M&A Deal Summary |
|
|---|---|
| Date | 2012-10-31 |
| Target | Pharmaco Hf. |
| Sector | Medical Products |
| Buyer(s) | Watson Pharmaceuticals |
| Deal Type | Add-on Acquisition |
| Deal Value | 4.3B EUR |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1931 |
| Sector | Medical Products |
| Employees | 1,325 |
Watson Pharmaceuticals, Inc.,is a specialty pharmaceutical company that develops, manufactures, markets and distributes branded and generic pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.
| DEAL STATS | # |
|---|---|
| Overall | 8 of 9 |
| Sector: Medical Products M&A | 3 of 4 |
| Type: Add-on Acquisition M&A Deals | 4 of 5 |
| Country: Iceland M&A | 1 of 1 |
| Year: 2012 M&A | 2 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2012-01-24 |
Ascent Pharmahealth
Melbourne, Australia Ascent Pharmahealth Ltd, markets in Australia, Singapore, Malaysia, Hong Kong, Vietnam, Thailand and other Asian countries with a range of generic pharmaceuticals, consumer skincare and over the-counter (OTC) medicines. Ascent has a regional manufacturing facility located in Singapore which manufactures prescription and OTC products in varied dosage forms for the Southeast Asia market. |
Buy | AU$375M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-01-23 |
Uteron Pharma SA
Grâce-Hollogne, Belgium Uteron Pharma SA is a development-based company dedicated to female healthcare. Uteron has a diversified portfolio of innovative products in different stages of development. The product development portfolio includes a hormonal IUD, a next generation oral contraceptives containing natural estrogen, a new generation of biochemical tests that will significantly increase in-vitro fertilization success rates, and pharmacologic treatments for cervical dysplasia. |
Buy | $150M |
